The monoamine oxidase A (MAO-A) has been suggested to be involved in the pathogenesis
as well as the pharmacological treatment of Major Depression. In the present study, 340 …

Genetic differences among patients suffering from Major Depression are likely to contribute
to interindividual differences in medication treatment response. Thus, the identification of …

Monoamine oxidase A (MAOA), a mitochondrial enzyme involved in the degradation of
biogenic amines, may be implicated in the pathogenesis of major depressive disorder …

Background Polymorphisms in the monoamine oxidase A (MAOA) gene may influence
treatment outcomes in major depression disorder (MDD). Objective To investigate the …

It has been proposed that an MAOA abnormality may be an important factor in the
development of major depressive disorder (MDD). Various polymorphisms of the MAOA …

Various polymorphisms of the X‐chromosomal monoamine oxidase A (MAO‐A) gene were
investigated for association with affective disorders. However, none of the studied variants …

Monoamine oxidase A (MAOA) is one of the key enzymes in the metabolism of
monoaminergic neurotransmitters which supposedly play an important role in the etiology of …

Objective Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes
biogenic amine neurotransmitters such as dopamine and serotonin. Individuals with atypical …

Major depressive disorder (MDD) is the leading cause of disability worldwide. Treatment
with antidepressant drugs (ATD), which target monoamine neurotransmitters including …

The monoamine oxidase A (MAO-A) gene has been suggested to be involved in the
pathogenesis as well as the pharmacological treatment of major depressive disorder. In the …